根治性前列腺切除术后盆腔淋巴结复发的放疗:临床实践中的患者选择
该研究收集14家瑞士放射肿瘤中心的治疗建议并转化为决策树,采用客观共识方法学评估差异与共识。结果显示PSMA PET/CT被93%的中心推荐用于再分期;不适合患者多推荐单纯ADT,适合且肿瘤特征不利者多数推荐ENRT+ADT,有利特征者共识度低、选择差异大。
要点
- PSMA PET/CT被93%的中心推荐作为再分期手段。
- 适合且肿瘤特征不利的1-4个病灶患者,57-71%的中心推荐ENRT+ADT。
- 1-4个淋巴结病灶中64%的中心提供焦点SBRT,多为5次分割。
核心结论
- 对于根治性前列腺切除术后盆腔淋巴结寡复发的患者,ENRT或SBRT可作为ADT的替代方案提供给经选择的患者,但各中心间治疗选择差异较大。
- 淋巴结的确切数量对治疗选择有重大影响。
研究设计与样本
- 收集14家瑞士放射肿瘤中心的治疗建议并转化为决策树,采用客观共识方法学进行迭代评估。
主要发现
- 93%的中心推荐PSMA PET/CT作为再分期方式。
- 对由年龄、合并症或低体能状态定义的不适合患者,超过70%推荐单纯ADT。
- 对适合且具有短PSA倍增时间或初始高危疾病等不利肿瘤特征的患者,多数中心(57-71%)对1-4个病灶推荐ENRT+ADT。
- 对适合且肿瘤特征有利的患者,共识水平低且推荐意见多样。
- 对1-4个淋巴结病灶,64%的中心提供焦点SBRT,最常为5次分割疗程。
关键数值与推荐
- PSMA PET/CT:93%的中心推荐。
- 不适合患者单纯ADT:超过70%的中心推荐。
- 适合且肿瘤特征不利、1-4个病灶:57-71%的中心推荐ENRT+ADT。
- 1-4个淋巴结病灶焦点SBRT:64%的中心提供,最常为5次分割。
临床怎么用
- 对不适合患者可考虑单纯ADT,对适合且肿瘤特征不利的1-4个病灶患者可考虑ENRT+ADT。
- 焦点SBRT可作为1-4个淋巴结病灶的选择之一,常采用5次分割方案。
- 治疗决策需结合PSMA PET/CT再分期及淋巴结确切数量。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: There is no general consensus on the optimal treatment for prostate cancer (PC) patients with intrapelvic nodal oligorecurrences after radical prostatectomy. Besides androgen deprivation therapy (ADT) as standard of care, both elective nodal radiotherapy (ENRT) and stereotactic body radiotherapy (SBRT) as well as salvage lymph node dissection (sLND) are common treatment options. The aim of our study was to assess decision making and practice patterns for salvage radiotherapy (RT) in this setting. METHODS: Treatment recommendations from 14 Swiss radiation oncology centers were collected and converted into decision trees. An iterative process using the objective consensus methodology was applied to assess differences and consensus. RESULTS: PSMA PET/CT was recommended by 93% of the centers as restaging modality. For unfit patients defined by age, comorbidities or low performance status, androgen deprivation therapy (ADT) alone was recommended by more than 70%. For fit patients with unfavorable tumor characteristics such as short prostate-specific antigen (PSA) doubling time or initial high-risk disease, the majority of the centers (57-71%) recommended ENRT + ADT for 1-4 lesions. For fit patients with favorable tumor characteristics, there were low levels of consensus and a wide variety of recommendations. For 1-4 nodal lesions, focal SBRT was offered by 64% of the centers, most commonly as a 5-fraction course. CONCLUSIONS: As an alternative to ADT, ENRT or SBRT for pelvic nodal oligorecurrences of PC are commonly offered to selected patients, with large treatment variations between centers. The exact number of lymph nodes had a major impact on treatment selection.
引用
- Panje C, Zilli T, Dal Pra A, et al. Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. Radiat Oncol. 2019. PMID: 31619296. doi:10.1186/s13014-019-1383-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。